The Lustgarten Foundation Awards $5 Million Grant to Break Through Cancer
The Lustgarten Foundation has awarded a $5 million grant to Break Through Cancer to target KRAS in pancreatic cancer.
The Lustgarten Foundation has awarded a $5 million grant to Break Through Cancer to target KRAS in pancreatic cancer.
Two clinical trials in the Lustgarten Foundation’s Clinical Accelerator are testing different combinations of immunotherapy.
Dr. Elizabeth Jaffee explains the importance of Lustgarten’s Clinical Accelerator Initiative to speed up the time from bench to trial.
Facing a new reality of having one of the toughest-to-treat cancers can indeed be overwhelming. That’s why it’s so important to make sure your treatment plan is the best possible one for you, say experts. One way to do that is with a second opinion. The reasons why pancreatic cancer patients seek second opinions are…
New clinical guidelines from the American Society for Radiation Oncology will help clarify the best uses of radiation treatment for pancreatic cancer.
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Dr. Brian Wolpin has found that about 1/3 of pancreatic cancer patients may benefit from genetic sequencing to determine treatment.
An international team of researchers led by Dr. David Tuveson has found that organoids can predict how pancreatic cancer patients will respond to different treatments.
Dr. David Tuveson has been appointed the chief scientist for the Lustgarten Foundation. He specializes in pancreatic cancer reseach at the Cold Spring Harbor Labs.